The Approach to Heparin-Induced Thrombocytopenia

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by platelet-activating antibodies that recognize multimolecular complexes of platelet factor 4 (PF4) bound to heparin. HIT is an intense hypercoagulability state (increased thrombin generation in vivo) that is complicated more often by venous thromboembolism (deep vein thrombosis, pulmonary embolism) than by arterial thrombosis. HIT is a risk factor for coumarin-induced microthrombosis, particularly affecting acral regions of limbs with deep vein thrombosis (venous limb gangrene). Coumarins (e.g., warfarin) are therefore contraindicated during the acute (thrombocytopenic) phase of HIT. Venous thromboembolism can occur early during an episode of HIT, sometimes even before HIT-associated platelet count declines become clear. Recognition of HIT may be facilitated through the use of a clinical scoring system, the 4Ts (thrombocytopenia, thrombosis, timing, and other explanations). Anti-PF4/polyanion enzyme-immunoassays (EIAs) and washed platelet activation assays readily detect HIT antibodies, and thus have high diagnostic sensitivity; however, only the platelet activation assays have high diagnostic specificity, suggesting that HIT is likely to be overdiagnosed in settings where EIAs are used exclusively for diagnosis. Treatment of HIT emphasizes substitution of heparin with an alternative nonheparin anticoagulant, such as a direct thrombin inhibitor (lepirudin, argatroban), or an indirect (antithrombin-mediated) inhibitor of factor Xa (danaparoid, fondaparinux?).

Heparin-induced thrombocytopenia - hypercoagulability state - venous thromboembolism - coumarin-induced microthrombosis - 4Ts scoring system

REFERENCES

• 1 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121 535-555
• 2 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York; Informa Healthcare USA 2007: 21-66
• 3 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York; Informa Healthcare USA 2007: 67-116
• 4 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
• 5 Warkentin T E, Roberts R S, Hirsh J, Kelton J G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.  Arch Intern Med. 2003;  163 2518-2524
• 6 Warkentin T E, Elavathil L J, Hayward C PM, Johnston M A, Russett J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med. 1997;  127 804-812
• 7 Warkentin T E, Sheppard J I, Sigouin C S, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia.  Blood. 2006;  108 2937-2941 , [Epub 2006 Jul 20]
• 8 Greinacher A, Gopinadhan M, Guenther J U et al.. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.  Arterioscler Thromb Vasc Biol. 2006;  26 2386-2393 , [Epub 2006 Jul 27]
• 9 Li Z Q, Liu W, Park K S et al.. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.  Blood. 2002;  99 1230-1236
• 10 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
• 11 Wallis D E, Workman D L, Lewis B E, Steen L, Pifarre R, Moran J F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.  Am J Med. 1999;  106 629-635
• 12 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.  J Thromb Haemost. 2006;  4 759-765
• 13 Warkentin T E. Drug-induced immune-mediated thrombocytopenia: from purpura to thrombosis.  N Engl J Med. 2007;  356 891-893
• 14 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344 1286-1292
• 15 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis.  Ann Intern Med. 2001;  135 502-506
• 16 Warkentin T E, Bernstein R A. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin [letter].  N Engl J Med. 2003;  348 1067-1069
• 17 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.  Thromb Res. 2003;  110 73-82
• 18 Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin T E, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients.  Thromb Haemost. 2005;  94 132-135
• 19 Warkentin T E, Sheppard J I. Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT).  J Thromb Haemost. 2007;  5 636-637 , [Epub 8 Dec 2006]
• 20 Levine R L, McCollum D, Hursting M J. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?.  Chest. 2006;  130 681-687
• 21 Warkentin T E. Think of HIT when thrombosis follows heparin.  Chest. 2006;  130 631-632
• 22 Greinacher A, Eichler P, Lietz T, Warkentin T E. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lower the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia [letter].  Blood. 2005;  106 2921-2922
• 23 Warkentin T E, Cook R J, Marder V J et al.. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.  Blood. 2005;  106 3791-3796 , [Epub 2005 Aug 18]
• 24 Warkentin T E. History of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York; Informa Healthcare USA 2007: 1-19
• 25 Warkentin T E, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York; Informa Healthcare USA 2007: 227-60
• 26 Warkentin T E, Sheppard J I. Testing for heparin-induced thrombocytopenia antibodies.  Transfus Med Rev. 2006;  20 259-272
• 27 Warkentin T E, Sheppard J I, Moore J C, Moore K M, Sigouin C S, Kelton J G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?.  J Lab Clin Med. 2005;  146 341-346
• 28 Lo G K, Sigouin C S, Warkentin T E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?.  Am J Hematol. 2007;  82 1037-1043
• 29 Warkentin T E, Greinacher A. Appendix 12. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York; Informa Healthcare USA 2007: 544
• 30 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(Suppl) 311S-337S
• 31 Greinacher A, Warkentin T E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York; Informa Healthcare USA 2007: 283-317
• 32 Warkentin T E. Coumarin-induced skin necrosis and venous limb gangrene. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. New York; Lippincott Williams & Wilkins 2006: 1663-1671
• 33 Warkentin T E. Should vitamin K be administered when HIT is diagnosed after administration of coumarin ? [letter].  J Thromb Haemost. 2006;  4 894-896
• 34 Warkentin T E. Bivalent direct thrombin inhibitors: hirudin and bivalirudin.  Best Pract Res Clin Haematol. 2004;  17 105-125
• 35 Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.  Expert Rev Cardiovasc Ther. 2004;  2 339-357
• 36 Lubenow N, Eichler P, Lietz T, Greinacher A. and the HIT Investigators Group . Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HIT-1, HAT-2, and HAT-3.  J Thromb Haemost. 2005;  3 2428-2436
• 37 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
• 38 Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.  Blood. 2004;  104 3072-3077
• 39 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.  Circulation. 2003;  108 2062-2065
• 40 Lewis B E, Wallis D E, Berkowitz S D, Matthai W H et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
• 41 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
• 42 Kodityal S, Nguyen P H, Kodityal A, Sherer J, Hursting M J, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital.  J Intensive Care Med. 2006;  21 86-92
• 43 Chong B H, Ismail F, Cade J, Gallus A S, Gordon S, Chesterman C N. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172.  Blood. 1989;  73 1592-1596